Dr. Reddy’s Laboratories. has filed a patent for 6-substituted pyridazine compounds that act as SMARCA2 and/or SMARCA4 degraders, useful in treating diseases dependent on these proteins. The patent also covers the preparation of these compounds and pharmaceutical compositions containing them. GlobalData’s report on Dr. Reddy’s Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dr. Reddy's Laboratories, Cancer treatment biomarkers was a key innovation area identified from patents. Dr. Reddy's Laboratories's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240018134A1) discloses a compound of formula (I) and its various derivatives for use in degrading target proteins such as SMARCA2 or SMARCA4, which are associated with certain diseases. The compound can be selected from different formulas (IA, IB, IC, ID) with specific substitutions and configurations. The patent also covers pharmaceutical compositions containing the compound, methods for treating diseases dependent on SMARCA2 or SMARCA4, and inhibiting tumor growth in cancer patients. The compounds can be administered to subjects in need of treatment, with specific applications in various types of cancer, including hematologic cancers, lung cancer, breast cancer, and others.
Furthermore, the patent application includes detailed descriptions of the compounds' chemical structures, including the substituents and configurations that can be present in the molecules. The compounds can be administered as pharmaceutically acceptable salts, stereoisomers, tautomers, or prodrugs, along with suitable carriers or excipients. The methods described in the patent application aim to target specific proteins involved in disease progression, offering potential therapeutic benefits in treating or delaying the progression of various disorders. The compounds' effectiveness in inhibiting tumor growth in cancer patients is highlighted, with a focus on a wide range of cancer types, including leukemia, lymphoma, sarcoma, and solid tumors affecting different organs. Overall, the patent application presents a comprehensive approach to utilizing these compounds for therapeutic purposes, particularly in the context of targeting specific proteins associated with disease pathology.
To know more about GlobalData’s detailed insights on Dr. Reddy's Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
